


Selpercatinib LIBRETTO-001 (Cohort 3)

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Selpercatinib LIBRETTO-001 (Cohort 3)

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Endocrine Tumours  
Therapeutic Indication: Treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)  
Experimental Arm: Selpercatinib  
Control Arm: Single arm

